The ASCEND program aims to:
- Characterise morbidity and mortality among people with problematic drug use;
- Enhance the effectiveness of drug dependence management;
- Evaluate strategies to eliminate hepatitis C virus (HCV) infection among people who inject drugs; and
- Monitor trends in drug dependence and HCV burden in Australia.
The Investigators are undertaking a five-year program grant seeking to enhance collaboration and bring together disciplines of viral hepatitis and drug dependence for mutual benefit.
Read more on the NDARC website.
